Nov 20, 2019 — 4 min read
A leading medical AI company, Lunit, announced today the certification of CE mark for its most up-to-date chest x-ray analysis AI, Lunit INSIGHT CXR. The software provides analysis of chest x-ray images, detecting major findings that can lead to the most common lung diseases.
The CE mark enables the company to provide the AI solution to European healthcare institutions that conduct chest x-ray screenings, which is a widely-used method of basic imaging tests. According to the company, Lunit INSIGHT CXR is designed to help increase accuracy to detect more findings and alleviate the burden of radiologists who conduct routine chest x-ray interpretations.
“We are delighted to announce that one of our most mature products, Lunit INSIGHT CXR, has won CE marking,” said Brandon Suh, MD, CEO of Lunit. “We look forward to installations among hospitals across Europe, where an improvement in healthcare services in the region can greatly impact many people’s lives.”
Lunit INSIGHT CXR (ver. 3) detects 10 major chest abnormalities including nodule, calcification, pneumothorax, consolidation, fibrosis, and more, also supporting tuberculosis (TB) screening. The detection accuracy reaches at average 98.7%.
The AI analysis results are presented on the chest x-ray image, providing the location information and the abnormality score, which reflects the probability of the existence of the detected findings. The software also generates case reports that summarize the evaluation for each case, conducted by the AI.
According to Lunit, the software has been highlighted recently in major publications such as Radiology, Scientific Reports, JAMA Open Network, and Clinical Infectious Diseases. The publications validate the performance of Lunit INSIGHT CXR as well as its clinical value in an emergency department and TB screening setting.
“Lunit INSIGHT CXR has been evolving ever since its first introduction at RSNA 2017,” said Sunggyun Park, PhD, Head of Chest Radiology at Lunit. “According to our reader study published in Radiology, our product can greatly improve reader performance by 20% at the highest. It can support radiologists to gain efficiency in the day to day workflow.”
The product is currently clinically installed for use in Mexico, UAE, China, Thailand, and Korea.
More than 2.3 million images from over 80 countries have been analyzed through a public demo of the software since its launch two years ago. The demo is publicly available at https://insight.lunit.io as pictured below.
Lunit INSIGHT CXR will be presented at RSNA 2019, scheduled to be held on 1-5 December, at Chicago. Lunit booth will be located in AI Showcase, booth #10732. The demo will be also available at partner booths: FUJIFILM REiLi, GE Healthcare and INFINITT.
Lunit is a medical AI software company devoted to developing advanced medical image analytics and novel imaging biomarkers via cutting-edge deep learning technology. Founded in 2013, Lunit has been internationally acknowledged for its advanced, state-of-the-art technology and its application in medical images with high accuracy and efficiency. Lunit’s AI solution for chest x-ray and mammography, Lunit INSIGHT, is currently in use at different locations around the world—Mexico, UAE, China, Thailand, and Korea. Lunit is based in Seoul, South Korea.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
ANNOUNCING: BRANDON SUH, OUR NEW CEO
Lunit preps Korean IPO led by NH Investment Bank
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Introduce Medical AI Solutions at GTC 2019
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Named to the 2019 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
Lunit Secures $26M in Series C Funding Round, Led by Asian Investors
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Renowned Oncologist Dr. Tony Mok Joins Lunit Advisory Board
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit Awarded as Technology Pioneer by World Economic Forum
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Lunit Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021
Clinical Application of Lunit AI For Chest Radiography and Mammography to Be Presented at AOCR 2021
Lunit Secures $26M Investment from Guardant Health in a Strategic Funding Round
A Multi-reader Study Finds Unnecessary CT Exams Can Be Reduced by 30% When Analyzing Chest Radiographs with AI
Fujifilm Introduces its AI-powered Product for Chest X-ray in Japan, in Collaboration with Lunit
Lunit Collaborates with Intel to Provide AI Solutions to CPU-Based Customers in Need of Effective X-ray Diagnosis
Lunit AI Applied to Clinical Trial for Drug Development for the First Time--Findings Presented at ESMO 2021